Nathan Tholl, MD
Family Medicine · Goodyear, AZNPI 1124480165
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 28.2% of the total. Reporting peaked in 2020 at $1,605 and has fallen 85.9% since, to $227 in 2025.
Across 158 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$672
- GSK$271
- Johnson & Johnson$225
- AstraZeneca$200
- Boehringer Ingelheim$158
- AbbVie$134
- plus $723 from 15 others
What the payments were for
- Food & beverage$2,384100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $672 |
| GSK | 31 | $271 |
| Johnson & Johnson | 7 | $225 |
| AstraZeneca | 12 | $200 |
| Boehringer Ingelheim | 9 | $158 |
| AbbVie(2 entities) | 8 | $134 |
| Amgen | 7 | $123 |
| Amarin Pharma, Inc. | 8 | $123 |
| Sanofi-aventis U.S. LLC | 5 | $77 |
| Daiichi Sankyo Inc. | 4 | $71 |
| Merck | 4 | $65 |
| Lilly USA, LLC | 3 | $47 |
| Redhill Biopharma Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Eisai Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$125
How this compares
$2,384 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 158 | $236,982 |
| JardianceEmpagliflozin | 54 | $95,745 |
| FarxigaDapagliflozin Propanediol | 68 | $81,201 |
| TrulicityDulaglutide | 32 | $53,705 |
| JanuviaSitagliptin Phosphate | 31 | $46,978 |
| EliquisApixaban | 26 | $45,264 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $27,241 |
| WegovySemaglutide | 14 | $18,759 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $15,416 |
| Atorvastatin Calcium | 1,137 | $10,898 |
| TopamaxTopiramate | 11 | $8,312 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,221 |
| Omega-3 Acid Ethyl Esters | 44 | $5,054 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $4,803 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $4,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $672 | $255,741172 claims |
| Boehringer IngelheimJardiance | $158 | $95,74554 claims |
| AstraZenecaFarxiga, Symbicort | $200 | $87,42185 claims |
| Lilly USA, LLCTrulicity | $47 | $53,70532 claims |
| MerckJanuvia | $65 | $46,97831 claims |
| GSKTrelegy Ellipta | $271 | $27,24120 claims |
| Sanofi-aventis U.S. LLCLantus | $77 | $3,14522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Goodyear
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
- Heather ElwoodPhoenix$236K
- Ryan CaseyYuma$231K
- Suzanne BentzMesa$174K
- Brent AllanParadise Valley$108K
- Ahmed AghaPhoenix$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.